Slowed Heart Rate

Bradycardia, characterized by a slowed heart rate (less than 60 beats per minute in adults), results from disruptions in the heart's electrical conduction system or extrinsic factors influencing cardiac rhythm. Below is a description of the key events involved in the manifestation of bradycardia:

1. Clinical Measurements

a. Electrocardiogram (ECG)

• Purpose: The gold standard for detecting bradycardia and evaluating heart rhythm.
• Key Findings:
  • Heart rate < 60 bpm (measured from R-R intervals).
  • Prolonged PR interval (indicating slowed atrioventricular conduction).
  • Sinus bradycardia: Normal P wave followed by a QRS complex.
  • Bradyarrhythmias (e.g., AV blocks, junctional rhythms).
• Types:
  • Resting ECG: Snapshot of heart rhythm at rest.
  • Holter Monitor: Continuous 24–48-hour monitoring to detect intermittent bradycardia.
  • Event Recorder: Used for longer-term monitoring in symptomatic patients.

b. Heart Rate Monitoring

• Purpose: Simplified method to detect bradycardia.
• Devices:
  • Manual pulse check (radial or carotid artery).
  • Wearable heart monitors (e.g., smartwatches, fitness trackers).
  • Bedside monitors in clinical settings.
• Parameters: Beats per minute (bpm) measured over 30–60 seconds.

c. Stress Testing

• Purpose: To observe heart rate response to exercise.
• Findings:
  • Bradycardia persisting during exercise indicates underlying pathology.

2. Electrophysiological Techniques

a. Electrophysiology Study (EPS)

• Purpose: Detailed mapping of the heart’s electrical conduction system.
• Procedure:
  • Invasive catheter placement in the heart to measure conduction times and locate areas of delayed or blocked conduction.
• Application:
  • Identifies the site of dysfunction (e.g., SA node, AV node, His-Purkinje system).

b. Optical Mapping

• Purpose: Visualizes electrical activity in cardiac tissues using voltage-sensitive dyes.
• Application:
  • In research settings to detect localized slowing in conduction velocity or pacemaker activity.

3. Molecular and Cellular Measurements

a. Patch-Clamp Recording

• Purpose: Directly measures ion channel activity in isolated pacemaker cells or conduction tissue.
• Key Findings:
  • Reduced activity of HCN channels (funny current, If).
  • Altered L-type calcium channel activity in SA or AV node cells.

b. Calcium Imaging

• Purpose: Detects intracellular calcium cycling abnormalities in pacemaker cells.
• Method: Use of calcium-sensitive dyes (e.g., Fluo-4, Fura-2) to track calcium transients.

c. Molecular Profiling

• Purpose: Detects genetic or molecular abnormalities linked to bradycardia.
• Techniques:
  • qPCR, Western Blot, Immunostaining: Measures expression of ion channels (e.g., HCN4, Cav1.3, Kv channels).
  • Connexin Studies: Evaluates gap junction proteins (e.g., Connexin 43, 45) for conduction abnormalities.

4. Imaging Techniques

a. Echocardiography

• Purpose: Non-invasive visualization of cardiac structure and function.
• Findings:
  • Evaluates structural causes (e.g., fibrosis, chamber enlargement) contributing to bradycardia.
  • Assesses stroke volume and cardiac output.

b. MRI or CT Scans

• Purpose: Advanced imaging for structural abnormalities in the conduction system.
• Applications:
  • Detects fibrosis or infiltrative diseases affecting the SA or AV node.

5. Reflex Testing

a. Valsalva Maneuver

• Purpose: Tests autonomic control over heart rate.
• Findings:
  • Bradycardia triggered by exaggerated vagal response.

b. Carotid Sinus Massage

• Purpose: Evaluates baroreceptor sensitivity in suspected reflex bradycardia.
• Procedure: Gentle massage of the carotid sinus to observe bradycardia response.

6. Genetic Testing

• Purpose: Identifies hereditary conditions predisposing to bradycardia.
• Techniques:
  • Whole-genome or targeted sequencing for mutations in HCN4, SCN5A, or other related genes.
• Applications: Useful in familial or congenital bradycardia cases.

7. Blood Tests

• Purpose: Detects systemic or metabolic causes of bradycardia.
• Parameters:
  • Electrolyte levels (e.g., hyperkalemia or hypokalemia).
  • Thyroid function (e.g., hypothyroidism leading to reduced heart rate).
  • Drug toxicity levels (e.g., digoxin or beta-blockers).

1. Impaired Pacemaker Activity in the SA Node

• Event Description:
  • The sinoatrial (SA) node is the heart's primary pacemaker, responsible for initiating electrical impulses. Reduced automaticity of the SA node leads to a decrease in impulse generation.
• Causes:
  • Dysfunction of HCN channels (funny current, If).
  • Reduced sympathetic stimulation or increased parasympathetic activity.
  • Intrinsic damage or fibrosis in the SA node.
• Impact: Slower generation of action potentials, resulting in a reduced heart rate.

2. Delayed Atrioventricular (AV) Conduction

• Event Description:
  • The AV node conducts impulses from the atria to the ventricles. Delayed conduction through the AV node can prolong the PR interval or result in blocked impulses.
• Causes:
  • Impaired L-type Ca²⁺ channel activity.
  • Increased vagal tone reducing conduction velocity.
  • Structural changes (fibrosis or ischemia) in the AV node.
• Impact: Slowed transmission of impulses, contributing to bradycardia or heart block.

3. Reduced Impulse Propagation in the His-Purkinje System

• Event Description:
  • Electrical signals are transmitted to the ventricles via the His-Purkinje system. Slowed conduction in this system can reduce the overall heart rate.
• Causes:
  • Degenerative changes or fibrosis in the conduction system.
  • Blocked or slowed conduction due to electrolyte imbalances (e.g., hyperkalemia).
• Impact: Prolonged QRS duration and bradycardia.

4. Extrinsic Modulation by the Autonomic Nervous System

• Event Description:
  • Autonomic nervous system imbalance can modulate the heart rate:
    • Increased parasympathetic (vagal) tone slows the SA and AV nodes.
    • Decreased sympathetic tone reduces pacemaker activity and conduction velocity.
• Causes:
  • Reflex bradycardia (e.g., carotid sinus stimulation).
  • Neurogenic factors (e.g., vasovagal syncope).
• Impact: Systemic slowing of the heart rate.

5. Pharmacological or Exogenous Influences

• Event Description:
  • Certain drugs or toxins directly affect the ion channels and conduction pathways involved in cardiac pacing and conduction.
• Common Agents:
  • Beta-blockers (reduce sympathetic tone).
  • Calcium channel blockers (slow SA and AV nodal activity).
  • Antiarrhythmic drugs (e.g., amiodarone, digoxin).
• Impact: Bradycardia as a side effect or intended pharmacological action.

6. Structural Remodeling of the Conduction System

• Event Description:
  • Age-related or pathological remodeling (e.g., fibrosis, ischemia) of the heart's conduction system slows electrical signal propagation.
• Causes:
  • Aging, ischemic heart disease, myocarditis.
  • Infiltrative diseases (e.g., sarcoidosis, amyloidosis).
• Impact: Chronic bradycardia due to impaired conduction pathways.

7. Metabolic and Endocrine Influences

• Event Description:
  • Metabolic or hormonal imbalances alter the electrophysiological properties of the heart.
• Examples:
  • Hypothyroidism: Reduces metabolic activity and heart rate.
  • Hyperkalemia: Depresses conduction velocity and automaticity.
• Impact: Bradycardia as a systemic effect.

8. Genetic and Congenital Factors

• Event Description:
  • Mutations in genes coding for ion channels or gap junction proteins affect pacemaker activity and conduction.
• Examples:
  • HCN4 mutations: Impair If current and pacemaker activity.
  • SCN5A mutations: Affect sodium channel function in conduction.
• Impact: Congenital bradycardia or predisposition to arrhythmias.

9. Environmental or Reflex Triggers

• Event Description:
  • External triggers can provoke reflexive or situational bradycardia.
• Examples:
  • Hypothermia: Slows metabolic and cardiac activity.
  • Valsalva maneuver or carotid sinus massage: Increases vagal stimulation.
• Impact: Temporary slowing of the heart rate.

Choi, B.-R., Ziv, O., & Salama, G. (2023). "Conduction delays across the specialized conduction system of the heart: Revisiting atrioventricular node (AVN) and Purkinje-ventricular junction (PVJ) delays." Frontiers in Cardiovascular Medicine, 10, 1158480.

Antzelevitch, C., & Yan, G.-X. (2016). "J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge." Heart Rhythm, 13(10), e295–e324.

Markiewicz-Łoskot, G., Kolarczyk, E., Mazurek, B., Łoskot, M., & Szydłowski, L. (2020). "Prolongation of electrocardiographic T wave parameters recorded during the head-up tilt table test as independent markers of syncope severity in children." International Journal of Environmental Research and Public Health, 17(18), 6605.

Schwartz, P. J., Ackerman, M. J., Antzelevitch, C., Bezzina, C. R., Borggrefe, M., Cuneo, B. F., & Wilde, A. A. M. (2020). "Inherited cardiac arrhythmias." Nature Reviews Disease Primers, 6(1), 58.

Di Diego, J. M., Patocskai, B., Barajas-Martinez, H., Borbáth, V., Ackerman, M. J., Burashnikov, A., & Antzelevitch, C. (2020). "Acacetin suppresses the electrocardiographic and arrhythmic manifestations of the J wave syndromes." PLOS ONE, 15(11), e0242747.